Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03024034 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 TP-271 Oral PK Single Ascending Dose Study
A Phase 1 study, sponsored by Tetraphase Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT03024034 is a Phase 1 study that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT03024034, a Phase 1 study, has completed, sponsored by Tetraphase Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of up to 6 different single ascending oral doses of TP-271, ranging from 25 mg to 300 mg, in healthy adult male or female subjects.
Interventions
- DRUG TP-271
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-03-02 |
| Est. Completion | 2018-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03024034
The ClinicalTrials.gov registry entry for NCT03024034 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TP-271 is the first listed.
NCT03024034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03024034 about?
NCT03024034 is a clinical study titled "A Phase 1 TP-271 Oral PK Single Ascending Dose Study". The purpose of this study is to determine the safety and tolerability of up to 6 different single ascending oral doses of TP-271, ranging from 25 mg to 300 mg, in healthy adult male or female subjects.
What is the current status of trial NCT03024034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2017-03-02. Estimated completion is 2018-06-04.
What interventions are being tested in trial NCT03024034?
The interventions under investigation include: TP-271 (DRUG).
Who is sponsoring clinical trial NCT03024034?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.